Kyowa Hakko Kirin’s first and only Rituxan (rituximab) biosimilar in Japan is showing a faster-than-expected uptake in the market, with the company racking up 4.3 billion yen from the cancer drug in 2018, far beyond its initial 3.2 billion yen…
TRENDS
Daiichi Sankyo Espha Sales Double as It Cashes In On Authorized Generic Boom
By Reiji Anasako The FY2017 earnings season saw a bonanza of authorized generics (AGs) as their major marketer, Daiichi Sankyo Espha, enjoyed sharp growth in its revenue, while original drug makers suffered steep sales declines in their flagship brands. The…
To read the full story
Related Article
TRENDS
- Rituxan Biosimilar Grabs 30% Volume Share in Just 1 Year; Sales Expected to Double in 2019
February 12, 2019
- Drug Formulary Initiatives Moving Beyond Hospitals, Generic Makers Prepping for Regional Lists
January 30, 2019
- Top 10 PHARMA JAPAN Stories in 2018
December 26, 2018
- Generic Industry at Crossroads: Companies Face Pressing Need to Boost Profitability ahead of FY2020
November 28, 2018
- Economic Benefits for Patients, Healthcare Providers Driving Biosimilar Sales Growth as Quality Worries Fade
November 15, 2018
Members of a key reimbursement policy panel appear to be becoming more and more open to the industry’s call for…
With a cursory glance, recruitment is easily defined. We’re here to help place candidates into the vacancies our clients need to fill. Armed with a pen and paper, you could even map out the process.• We study the market• We…
As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…